Bruker Provides Next-Generation Biopharmaceutical Characterization Solutions to Leading Pharma and Biotech Partners
12 September 2012 - 2:48AM
Business Wire
At the 2012 CASSS 9th Symposium on the Practical Applications of
Mass Spectrometry in the Biotechnology Industry, Bruker today
launches the first software solution to encompass the complete
biopharmaceutical characterization challenge, including glycoforms,
impurities and modifications. The unique BioPharmaCompass
1.1 software allows biotech customers to leverage Bruker’s
leadership in cutting-edge mass spectrometry for intact protein and
post-translational modification analysis in a routine industrial
biologics environment.
BioPharmaCompass 1.1 introduces several major enabling
innovations in the quest for a complete picture of biological
products for regulatory approval and compliance:
- Intact precise-mass product
confirmation and impurity identification in a single run
- Handling of multiple-point time-course
studies including impurity analysis and stress studies
- Antibody determination by top-down
sequencing, including antibody-drug conjugate analysis with instant
visualization of N and C terminal modification analysis against
expected batch standard
- Glycan profiling, PTM and artifact
determination, localization and quantification including novel ETD
(electron transfer dissociation) strategy for determination of
deamidation sites
- Rapid identity testing by peptide mass
fingerprinting using digest match chromatogram search, as well as
full software enablement of combined CID and ETD strategies for
100% sequence coverage even including formerly
difficult-to-sequence domains
- Automatic combination of data from
multiple enzymatic approaches
- The industry’s first automated glycan
profiling and identification workflow, expandable using Bruker’s
recently launched Glycoquesttm complete glycoprotein
analysis solution and integrated library, making sophisticated
glycoprotein identification and assignment as simple as a standard
protein database search, combining protein sequence and
glyco-structure sequencing data into a single 360 degree
report
Bruker has pioneered the field of novel mass spectrometry
techniques for the direct measurement and sequencing of intact
proteins. The industry-leading highest resolution maXis
ESI-QqTOF spectra available at maximum sensitivity for trace
impurities, patented top-down ISD-T3 sequencing on Flex
series MALDI TOF/TOF and best-in-class amazon ETD ion-trap
technology for PTM analysis are all critical steps in a complete
understanding of the composition of a biotherapeutic. Now,
BioPharmaCompass 1.1 enables biotech and pharmaceutical
customers to manage information from any or all of these unique
capabilities, dramatically speeding the licensing and production of
biological drugs.
Explaining the urgent need for the new solution, Dr. Ian
Sanders, President of the Bruker Daltonics Life Science Mass
Spectrometry division, commented: “The speed and completeness of
the analytical picture is vital to our customers securing
regulatory approval in this rapidly growing market. There is
continual pressure to stay one step ahead of regulatory
requirements and we aim to deliver the insight from the most
sophisticated new MS approaches with the minimum of expert
intervention required by the customer.”
Bruker’s launch follows successful trials by some of the leading
organizations in biotherapeutics. Dr. Alain Beck, Senior Director,
Antibody Physico-Chemistry, Center of Immunology at Pierre Fabre
commented: "We had a chance to work with Bruker's scientists on
antibody characterization by Mass Spectrometry including the use of
BioPharmaCompass. We were really impressed by the
performance of different complementary mass spectrometers as well
as the ability of the software to identify minor modifications in
the sequence."
The new development also delivers significant value in increased
productivity in the industrial environment. Dr. Malcolm Saxton,
Senior Scientist at Novozymes Biopharma, explained:
“BioPharmaCompass has allowed our laboratory to
significantly increase throughput. More samples are now analysed
while scientists are able to spend a higher proportion of their
time on complex problems and new method development. The automated
data analysis carried out through BioPharmaCompass ensures
high quality and, importantly, fully reproducible data is obtained,
reported and traceably stored ensuring that trained staff only
spend their time interrogating the samples that need further
inspection.”
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of
high-performance scientific instruments and solutions for molecular
and materials research, as well as for industrial and applied
analysis. For more information on Biopharma Compass and related
mass spectrometry systems, please visit www.bruker.com.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024